Literature DB >> 3539011

Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess.

H Thadepalli, S V Gollapudi, S K Chuah.   

Abstract

Difloxacin (A-56619) and A-56620, two novel fluoroquinolones, were tested in comparison with ciprofloxacin, cefoxitin, and combined clindamycin and gentamicin in the treatment of experimentally induced intraabdominal abscess associated with Bacteroides fragilis. Difloxacin was found to be as effective as clindamycin-gentamicin. A-56620, despite achieving subtherapeutic levels in serum, was found to be as effective as cefoxitin. Both difloxacin and A-56620 were effective in vivo against experimentally induced intra-abdominal abscess in rats.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3539011      PMCID: PMC176483          DOI: 10.1128/AAC.30.4.574

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

Authors:  E J Freireich; E A Gehan; D P Rall; L H Schmidt; H E Skipper
Journal:  Cancer Chemother Rep       Date:  1966-05

2.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

3.  Antimicrobial spectrum of Win 49375.

Authors:  N V Jacobus; F P Tally; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

4.  Antimicrobial therapy of experimental intraabdominal sepsis.

Authors:  W M Weinstein; A B Onderdonk; J G Bartlett; T J Louie; S L Gorbach
Journal:  J Infect Dis       Date:  1975-09       Impact factor: 5.226

5.  Therapy for experimental intraabdominal sepsis: comparison of four cephalosporins with clindamycin plus gentamicin.

Authors:  T J Louie; A B Onderdonk; S L Gorbach; J G Bartlett
Journal:  J Infect Dis       Date:  1977-03       Impact factor: 5.226

6.  In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.

Authors:  P B Fernandes; D T Chu; R R Bower; K P Jarvis; N R Ramer; N Shipkowitz
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

7.  The activity of enoxacin against clinical bacterial isolates in comparison with that of five other agents, and factors affecting that activity.

Authors:  D S Reeves; M J Bywater; H A Holt
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

8.  In vitro activity of ticarcillin against anaerobic bacteria compared with that of carbenicillin and penicillin.

Authors:  I Roy; V Bach; H Thadepalli
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

9.  Experimental intra-abdominal abscesses in rats: development of an experimental model.

Authors:  W M Weinstein; A B Onderdonk; J G Bartlett; S L Gorbach
Journal:  Infect Immun       Date:  1974-12       Impact factor: 3.441

10.  In vitro antibacterial activity of norfloxacin (MK-0366).

Authors:  A King; C Warren; K Shannon; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

View more
  7 in total

1.  In vivo effects of rufloxacin and ciprofloxacin on T-cell subsets and tumor necrosis factor production in mice infected with Bacteroides fragilis.

Authors:  S V Gollapudi; S K Chuah; T Harvey; H D Thadepalli; H Thadepalli
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

2.  In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.

Authors:  H Thadepalli; U Reddy; S K Chuah; F Thadepalli; C Malilay; R J Polzer; N Hanna; A Esfandiari; P Brown; S Gollapudi
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

3.  Use of lymphokines in treatment of experimental intra-abdominal abscess caused by Bacteroides fragilis.

Authors:  S V Gollapudi; A Gupta; H Thadepalli; A Perez
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

4.  Activity of difloxacin (A-56619) and A-56620 against clinical anaerobic bacteria in vitro.

Authors:  M B Bansal; H Thadepalli
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

Review 5.  Newly documented antimicrobial activity of quinolones.

Authors:  Y X Furet; J C Pechère
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 6.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

Review 7.  Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.

Authors:  Temilolu Idowu; Frank Schweizer
Journal:  Antibiotics (Basel)       Date:  2017-11-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.